News
Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political ...
Blacks and Hispanics are particularly affected by HIV, making up more than half (70 percent) of estimated new HIV infections ...
Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...
Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...
6d
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injectionThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...
Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...
An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...
Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...
CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...
Parents with children insured by Medicaid fear changes to the government program mean vaccines will no longer be covered.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results